Trial Information: 180 patients with relapsed indolent lymphoma, including follicular lymphoma, will be recruited to test GA101 (aka RO5072759) monotherapy. Although this is a Phase II trial, patients will be randomized to receive either GA101 monotherapy or rituximab monotherapy.
Background Information: GA101 is a new humanized anti-CD20 monoclonal antibody which shows promise as a potentially more effective agent than the current standard drug of choice in that class, rituximab. Both drugs were developed by Roche, which is now moving forward with direct comparative trials of the two drugs.
In previous trials, GA101 had a 55% response rate in relapsed and rituximab-refractory patients. Several Canadian locations are also engaged in a Phase III trial comparing GA101 plus bendamustine with bendamustine monotherapy.
Canadian Locations: Calgary, AB; Vancouver, BC; Kingston, ON; London, ON; Toronto, ON; and Montreal, QC.
For more information, see ClinicalTrials.gov.
No comments:
Post a Comment